Trial Profile
Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary) ; Cytarabine; Idarubicin
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 02 Feb 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 09 Mar 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.